Table 2. Toxin A-specific antigen-activated B cell frequencies by flow cytometry.
| Control CD19+ve/IgD-ve events (%) | Tox A488 CD19+ve/IgD-ve events (%) | Control CD19+ve/IgD+ve events (%) | Tox A488 CD19+ve/IgD+ve events (%) | |
|---|---|---|---|---|
| Patients with C. difficile- associated diarrhoea (n=18) † | 0.10 (0 - 0.54) | 0.91* (0.21-1.78) | 0.07 (0.01-0.9) | 0.90* (0.02-2.60) |
| IBD patients with C. difficile infection (n=2)† | 0, 0 | 1.26, 0.09 | 0.18, 0.21 | 1.24, 0.54 |
| Cystic fibrosis patients, asymptomatic carriers of C. difficile (n=2) | 0.08, 0 | 5.64, 1.14 | 0.04, 0.04 | 3.70, 1.42 |
| Cystic fibrosis patients, stool negative for C. difficile (n=2) | 0.08, 0.07 | 0.95, 0.45 | 0.06, 0.10 | 1.33, 0.86 |
*
p<0.0005, vs relevant control
†Peripheral blood mononuclear cells were studied within 10 days of onset of diarrhoea.